Hepatology

Immune-related adverse events

Questions discussed in this category

How do you approach restarting immunotherapy in a patient with metastatic melanoma who previously developed immune-mediated hepatitis (Grade 3), with liver enzymes now back to baseline levels?

Given the improvement in liver function, what factors should be considered before reinitiating immunotherapy?"

4 Answers available

Papers discussed in this category

Cancer chemotherapy and pharmacology, 2019 Aug 23

Clinical difference between discontinuation and retreatment with nivolumab after immune-related adverse events in patients with lung cancer.

Related Topics in Hepatology